Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409849 | SCV000485549 | likely pathogenic | GNE myopathy | 2016-01-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001390114 | SCV001591740 | pathogenic | GNE myopathy; Sialuria | 2023-10-20 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg337*) in the GNE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNE are known to be pathogenic (PMID: 24027297). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individuals with autosomal recessive GNE myopathy (PMID: 25986339, 29480215). This variant is also known as p.Arg306*. ClinVar contains an entry for this variant (Variation ID: 370285). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV001782866 | SCV002024878 | pathogenic | not provided | 2020-10-28 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005004141 | SCV002795254 | pathogenic | GNE myopathy; Sialuria; Thrombocytopenia 12 with or without myopathy | 2024-03-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000409849 | SCV005059618 | pathogenic | GNE myopathy | 2023-12-22 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000409849 | SCV002075657 | pathogenic | GNE myopathy | 2021-06-03 | no assertion criteria provided | clinical testing |